Core Insights - Inspira Technologies has transitioned from clinical validation to early commercial execution in 2025, with significant progress in commercialization pathways for the INSPIRA™ ART100 system [2] - The company reported initial revenues of approximately $289,000 for the year ended December 31, 2025, primarily from the ART100 system [6] - Inspira is focused on expanding its clinical and commercial deployment while converting its growing opportunity base into revenue throughout 2026 [2] Business and Operational Highlights - The ART100 system was successfully used in clinical procedures at leading medical centers, including lung transplants, marking a critical milestone in its clinical performance [3] - The company received vendor approval for the ART100, allowing it to enter formal procurement pathways across a major healthcare network [3] - Inspira appointed Mike Hershkovitz as Vice President of Global Sales to support its expansion efforts [4] Financial Performance - Research and development expenses increased to $7,496,000 in 2025 from $6,323,000 in 2024, primarily due to higher share-based compensation and exchange rate fluctuations [7] - General and administrative expenses rose to $5,532,000 in 2025 from $4,185,000 in 2024, driven by higher salary expenses and share-based compensation [8] - The net loss for the year ended December 31, 2025, was $13,220,000, compared to a loss of $11,053,000 in 2024 [10] Cash Position and Liquidity - Cash and cash equivalents totaled $3,159,000 as of December 31, 2025, down from $5,779,000 in 2024 [11] - The company completed a registered direct offering generating approximately $4.75 million in gross proceeds, enhancing its liquidity position [11] Strategic Evaluation - Inspira entered into a non-binding term sheet with Bio-View Ltd. for a proposed acquisition but later decided not to proceed with the transaction [5] - The company is currently evaluating strategic alternatives to generate significant shareholder value [5]

Core Insights - Inspira Technologies is planning a strategic expansion into liquid biopsy diagnostics, aiming to preserve shareholder value while enabling future dividend distributions from its core technologies [1][2] - The proposed acquisition of a liquid biopsy platform is seen as a significant value inflection point, enhancing Inspira's capabilities in blood-based diagnostics and real-time monitoring [2][3] Company Operations - Inspira has developed the HYLA™ blood sensor platform, achieving 95% to 99% accuracy in clinical testing, and has established a dedicated blood diagnostics laboratory to support its expansion into adjacent diagnostic applications [2][3] - The company’s FDA-cleared INSPIRA™ ART100 system is currently deployed in leading U.S. hospitals, contributing to a growing commercial pipeline expected to generate revenue in 2026 [7][8] Liquid Biopsy Technology - The targeted liquid biopsy platform analyzes intact circulating tumor cells (CTCs) from blood samples, providing a more direct view of tumor characteristics over time, which could significantly improve current diagnostic practices [3][4] - Initially focusing on breast cancer, the platform is designed for routine clinical use and has shown high concordance with traditional tissue biopsies, with potential adaptability across various solid tumor indications [5][6] Transaction Structure - The acquisition is structured to allow Inspira to acquire the liquid biopsy business in exchange for up to 40% of its issued and outstanding share capital, while ensuring existing shareholders benefit from the value generated by the core respiratory business through a Contingent Value Rights (CVR) framework [13] - A concurrent equity investment of $15 million is expected to support the integration of the liquid biopsy platform and the advancement of Inspira's existing operations, with a pre-money valuation of $180 million [13][9]

Core Viewpoint - Inspira Technologies is planning a strategic expansion into liquid biopsy diagnostics, aiming to preserve shareholder value while enabling future dividend distributions from its core respiratory and life-support technologies [1][2]. Company Strategy - The proposed acquisition of a liquid biopsy platform is seen as a significant value inflection point, enhancing Inspira's diagnostics capabilities with long-term potential [2]. - The transaction is structured to optimize value allocation between the new platform and Inspira's existing respiratory business through a Contingent Value Rights (CVR) framework [2][12]. - The acquisition is positioned as a natural extension of Inspira's competencies in blood-based diagnostics and real-time monitoring, leveraging its proprietary HYLA™ blood sensor platform [2][7]. Liquid Biopsy Technology - The targeted liquid biopsy platform analyzes intact circulating tumor cells (CTCs) from blood samples, offering a more direct view of tumor characteristics over time [3]. - Initial focus is on breast cancer, where changes in biomarkers can significantly impact treatment options, enabling minimally invasive testing to monitor tumor evolution [4][5]. - The technology is designed for routine clinical use and has shown high concordance with traditional tissue biopsy in preliminary validations, with plans for adaptability across various solid tumor indications [5][6]. Current Operations - Inspira's existing operations in respiratory care and life-support are advancing, with the FDA-cleared INSPIRA™ ART100 system deployed in leading U.S. hospitals [7]. - The company is expected to generate revenue from previously announced purchase orders during 2026 [7]. Financial Aspects - The proposed equity investment of up to $15 million is intended to support ongoing operations and further development of existing platforms, with $12 million specifically allocated for this purpose [8][12]. - The acquisition structure allows Inspira to acquire the liquid biopsy business in exchange for up to 40% of its issued share capital, ensuring economic benefits for current shareholders through the CVR framework [12]. Transaction Timeline - The acquisition and equity investment are expected to close concurrently, pending customary conditions, including shareholder and regulatory approvals, with a target for execution of definitive agreements within approximately four weeks from January 5, 2026 [12].